Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...